Current opinion advocates the use of nephrostomies in hormone naive patients with obstructive uropathy while hormone resistant patients require an individual approach. Patients undergoing a nephrostomy for uropathy were retrospectively analysed, with particular interest in hormone status and blood levels. Over a 46-month period, 26/112 nephrostomies were performed for prostate cancer induced uropathy. Survival was 226.5 days for hormone naive patients, 114.3 days in the responsive group and 100.2 days if resistant. Bilateral cases survived 72.1 days versus 157.6 days for unilateral patients. All patients should be considered for nephrostomy despite their hormone status.
Introduction
Urologists, oncologists and radiologists commonly face the dilemma of deciding whether a nephrostomy is suitable for patients with obstructive nephropathy. There is surprisingly little recent evidence to assist clinicians in advising patients whether decompression would be in their best interests and how this may affect their prognosis. Once hydronephrosis has been confirmed radiologically, nephrostomies are usually considered via the percutaneous route, especially when retrograde access to the ureter is impossible. In prostate cancer, current opinion suggests that hormone naive patients benefit significantly from a nephrostomy, while the gain for hormone resistant cases is less good. 1, 2 There are also no reliable prognostic markers to help in deciding who will derive significant benefit from a nephrostomy. In this study, we aimed to establish the role of urinary tract decompression in prostate cancer, with particular interest in the influence of hormone status and any potential factors that may help predict outcome.
Method
All patients who underwent a nephrostomy between the 1st of January 2001 and the 31st of October 2004 were retrospectively identified from the radiology department appointment system. All but one patient had radiological confirmation of hydronephrosis before their decompression, using ultrasound in 23/26 cases and computerised tomography in 2/26 patients. Nephrostomies were performed in the prone/oblique position under local anaesthesia, with appropriate prophylactic antibiotic cover. Antegrade ureteric stents were inserted at the time of nephrostomy, whenever it was feasible. Nephrostograms were later performed to confirm the position and patency of the stent and nephrostomy. The nephrostomy was then removed after a period of clamping providing the renal function was improving and urinary output was satisfactory.
Hospital notes were examined by one researcher for the following information; underlying condition, preand postnephrostomy urea, creatinine and PSA levels, hormone status, nephrostomy details, date of death, demographic details and length of any hospital stay. The trend of urea and creatinine levels was measured for 2 weeks postprocedure and the lowest level noted. Patients were defined as hormone escaped if they had a PSA 410 ng/ml or two consecutive PSA rises while on hormonal treatment.
Results
In this 46-month period, a total of 112 patients were identified who had undergone nephrostomy tube insertion, 72 male and 40 female. Twenty-six patients had ureteric obstruction secondary to prostatic malignancy. Of these, two were hormone naive (group one), three were responding to hormones (group two) and 21 were resistant to hormones (group three) prior to their nephrostomy. The age of the patients ranged from 65 to 89, with means for each group of 80, 76 and 75.5, respectively. PSA values ranged from 0.1 to 7359 ng/ml (mean 476 ng/ml, median 86.75 ng/ml). All 26 prostate patients had died by the end of the study period.
A total of 14 bilateral nephrostomies were performed, one patient each in groups one and two and twelve in group three (four were staged procedures). Twelve patients, therefore, had unilateral nephrostomies, five of which only had unilateral hydronephrosis on ultrasound. Of the 20 patients who had radiological evidence of bilateral hydronephrosis, 10 had simultaneous bilateral nephrostomies, four were staged procedures and six underwent single kidney decompression. Twenty patients had a stent inserted while six patients were too unwell for a subsequent stent or had no improvement in their renal function to justify the procedure. The mean survival for all unilateral nephrostomy patients was 157.6 days compared to 72.1 days for the bilateral group. In the bilateral group the mean survival for patients whose nephrostomies were staged was 75.8 days versus 70.6 days for those who had both kidneys diverted.
The mean time to death was 226.5 days in the hormone naive group, 114.3 days in the hormone responsive group and 100.2 days in the hormone resistant cases (range 1-453 days). The median time to death was 53 days in the resistant group.
All but one patient had abnormal renal function prior to their nephrostomy. Preprocedure urea levels for all groups ranged from 8.7 to 107.4 mmol/l (mean 35.5 mmol/l, median 30.8 mmol/l) and creatinine levels from 112 to 1280 mmol/l (mean 627.2 mmol/l, median 565 mmol/l). The mean improvement in renal function is illustrated in Table 1 . If the postprocedure urea and creatinine fell below 15 mmol/l and 250 mmol/l, respectively, the mean survival time was 192.4 and 186.5 days, respectively. However, if the renal function did not improve to these levels then the mean survival was 30.7 and 24.1 days, respectively. The results for each group are also shown in Table 1 .
Discussion
Current opinion suggests that the development of obstructive uropathy is a poor prognostic sign when compared to a matched population of prostate cancer patients without obstruction. 3 Most clinicians would advocate decompressing obstructed systems in hormone naïve patients whereas the use of a nephrostomy in hormone resistant cases would be more controversial and requires a more holistic and individual approach, based on patient age, history, evolution of the cancer as well as ethical and social considerations. 4 There are surprisingly few studies of hormone resistant prostate patients and many of those published are based on open nephrostomy. The widespread adoption of percutaneous nephrostomy has altered the suitability of patients for decompression in a group whose prognosis is known to be poor. 1, 5, 6 This is partly due to the reduced complication rate, which ranges from 4 to 26%, 2, 5, 7 and the relative ease and low cost of the procedure. We were surprised by the fact that we had treated so many more hormone resistant than naive men, but this did allow us to analyse a group of patients who are notoriously difficult to treat.
When we compared the outcomes for all patients having unilateral or bilateral nephrostomies, the unilateral group fared better (157 days versus 72 days). This concurs with Van Dykes' study 8 but differs from Chiou et al. 9 who felt that unilateral nephrostomy should only be performed in exceptional circumstances. It was also interesting to note that staged nephrostomies did not seem to confer any harm.
The most difficult decision a clinician faces in this population is who will benefit from decompression. Unfortunately no reliable prognostic indicators were identified in this study which corresponds with others' findings. 10 This study did not confirm the findings of Sandhu et al. 11 who found that an initial raised urea or positive bone scan were strongly predictive of a poor outlook and that an elevated creatinine was of marginal significance. Gleason grade, age, PSA and presenting renal function did not accurately predict survival benefit and we did not have robust data on the duration of individuals' disease or sufficient numbers of bone scans to be able to comment. However, there was benefit potential for all patients regardless of how high their presenting urea and creatinine was. The postoperative renal function, while understandably mirroring the success of the nephrostomy, gives clinicians a more accurate prognosis for patients and their families. In the hormone resistant cases, the mean survival time if the creatinine fell to o250 mmol/l, within a fortnight of a nephrostomy, was 187.5 days. All patients with a creatinine o250 mmol/l had a survival time, which was greater than the median. This compares favourably with a mean of just 20.8 days if the creatinine was 4250 mmol/ l. Similarly a postprocedure urea of o15 mmol/l led to a survival time of 196.1 days compared to 28.3 days if the urea was above 15 mmol/l. Again all patients with a low urea had a survival time above the median. While this assists with informing patients, it does necessitate some patients having a nephrostomy from which they may derive little benefit.
The survival results of our study in hormone resistant patients did not achieve the levels of other studies that had 1-year and 2-year survivals of 48/19% 9 and 1 whose mean survival of 80 days is similar to our mean of 100 days. Nevertheless there were patients who obtained significant survival benefit, in this study up to 453 days, but other authors described patients lasting up to 1167 days. 5 Clearly this may be of huge benefit to those patients and their families and a blanket policy of not decompressing individuals who are seemingly in the final stage of their disease would be unjust. Even more modest survival does allow patients to arrange their affairs and spend precious time with their families. With this in mind, 10/26 patients (38%) never left hospital care (8/21 hormone resistant cases) and patients spent an average of 33 days in a hospital from nephrostomy to death. These figures concur with the findings of Dowling 5 (41% of survival time spent in hospital) and Paul 1 (20-80%, depending on patient hormone status and whether nephrostomies were inserted). The case for nephrostomy insertion in hormone naïve patients is more obvious with decompression essential until all treatment options have been explored.
There is scope for further work in this field. There is a paucity of trials, especially with significant numbers, and very few have studied the effects on patients and partners on their quality of life. Some urologists advocate routinely involving palliative care in the decision to treat patients contemplating what is effectively a palliative procedure as they have found this to be extremely helpful. There may also be a role for advanced directives indicating patient preference especially as the cognitive function of patients is often reduced by their uraemia. This could be discussed when patients are felt to have escaped hormonal control, particularly if they have a high Gleason grade or rapidly progressive disease.
Conclusion
The management of obstructive uropathy poses many difficult decisions for the patient, their family and their medical team. However, this study suggests that some hormone resistant patients do benefit from intervention and the use of postoperative urea and creatinine can help with prognosis and informed consent. There is a paucity of large trials clarifying the use of nephrostomies, especially in hormone-resistant cases, which needs addressing to assist with a commonly faced dilemma.
